Comparison
CJC-1295 vs. Melanotan II
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
no data
121062-08-6
Molecular weight
3647.3 g/mol
1024.18 g/mol
Half-life
144 h
1 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Mechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
5
of which in humans
2
5
Effects recorded
3
4
Open conflicts
1
0
Documented adverse events
3
3